Milan, Nov 19. (Adnkronos Health) – New positive scientific evidence for the drug of hope against metastatic pancreatic cancer, daraxonrasib. A study conducted in Spain shows that these forms respond well to initial treatment with the molecule administered in combination with chemotherapy.
The daraxonrasib-chemo mix led to a substantial shrinkage of the neoplasm in patients with cancer spread to other parts of the body. The new results of the phase 1-2 clinical study coincide with World Pancreatic Cancer Day and are presented at the 38th Symposium on Molecular Targets and Cancer Therapeutics of Eortc (European Organisation for Research and Treatment of Cancer), Nci (National Cancer Institute) and Aacr (American Association for Cancer Research) in Barcelona. The lead researcher of the work stated that the drug combination not only reduced tumors but also showed an “encouraging prolonged control” of the disease when used in patients who had not previously received treatment for metastatic disease.
Pancreatic cancer, explains Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, “remains one of the most difficult cancers to treat, particularly because more than half of affected individuals present with disease that has already spread to other organs. We need effective treatments that can achieve deep responses and prolong disease control to curb this aggressive and devastating neoplasm. For most patients with previously untreated metastatic forms, chemo remains the basis of treatment. While this can reduce tumors by a modest amount and help some patients, cancer often develops resistance and begins to grow again.”
Most patients with metastatic pancreatic cancer treated with standard chemotherapy survive for 8-11 months, and only 3% are alive 5 years after diagnosis. Tumor shrinkage is observed in only 23-42% of patients treated with chemo, and most tumors start growing again after 5-6 months. “What is particularly encouraging about these new and updated results is that we are starting to see not only a higher percentage of tumor response rates, but also deeper responses and an almost doubling of the duration of disease control, which could ultimately translate into longer survival,” highlights Park. As of September 28, 61 patients had received the drug combination. The median follow-up was 18.3 months, ranging from 13.1 to 23.7 months. Tumors shrank or disappeared in 60.7% of patients (objective response rate), a figure that included complete responses in 8.2% of patients (where the neoplasm was no longer detectable), and additionally, tumors stopped growing in 90.2% of patients (disease control rate). The median time before tumors returned or started growing again was 12.8 months (median progression-free survival).
“This represents a potentially transformative advance in first-line treatment for patients with metastatic pancreatic cancer, already exceeding the upper range of historical overall survival of 8.5-11.1 months with conventional chemotherapy,” notes Park. More than 90% of pancreatic tumors have a mutation in the Ras gene that drives cancer growth. Ras acts as a molecular switch that tells cells when to grow. In pancreatic cancer, the switch gets stuck in the ‘on’ state, continuously sending signals that push cancer cells to divide and grow. This makes the Ras mutation a crucial target for new treatments, but until recently, it was not possible to successfully target it.
Daraxonrasib is designed to stop an active protein called Ras (On) and interfere with the signals that pancreatic cancer cells depend on for survival. The phase 1-2 study Rmc-Gi-102 combines daraxonrasib (200mg taken orally once daily) with standard chemo (gemcitabine and nab-paclitaxel intravenously on days 1 and 15 of each cycle) as a first-line treatment to test this hypothesis. “We are seeing remarkably deep tumor responses in a substantial percentage of patients, along with durable disease control, with a median progression-free survival greater than one year,” says Park.
The most common adverse side effects included rash, diarrhea, fatigue, and reactions known to be associated with chemo such as cytopenia (a reduction in some blood cells), which were adequately managed with standard medical interventions. Treatment discontinuation due to daraxonrasib-related side effects was rare, occurring in 5% of patients. “These more mature results” on the drug “are particularly exciting because we are now seeing not only substantial tumor shrinkage, including complete responses, but also durable disease control, with a median progression-free survival greater than 1 year, almost doubling what has been historically reported with standard chemo. It is important to note that the 12-month overall survival rate of 76.6% provides further information on the sustained clinical benefit.” But it must be clarified, the researcher continues, that “this is an early-stage study and the results must be interpreted with caution because patients were not compared with patients receiving only chemotherapy. The next step is to determine whether these remarkable early results translate into better outcomes in a large randomized clinical trial. This is exactly the question addressed by the global phase 3 RASolute-303 study, which is evaluating daraxonrasib both as a standalone treatment and in combination with gemcitabine and nab-paclitaxel, compared to chemotherapy alone.”
The results presented in Barcelona “show that the combined treatment could potentially significantly improve patients’ overall survival, as well as the time before tumors start growing again,” comments symposium chair Elena Garralda, co-director of the clinical research program at Vall d’Hebron Institute of Oncology, not involved in the study. The work is “one of many presented that demonstrate that it is now possible to target Ras mutations that drive cancer growth. It is important to emphasize that it shows how Ras-targeted therapies can be combined with existing treatments to achieve potentially more durable clinical benefits for patients and that administration can be immediately as first-line therapy, allowing for an early start in the course of advanced disease.” Ras mutations also drive other cancers, including some lung, intestinal, biliary tract, and gynecological neoplasms. Experts believe clinical studies would be needed for each of these diseases to verify whether the combination of daraxonrasib and chemo can improve patient outcomes.